Nctid:
NCT06221605
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D006506", "term"=>"Hepatitis A"}, {"id"=>"D006509", "term"=>"Hepatitis B"}, {"id"=>"D019694", "term"=>"Hepatitis B, Chronic"}, {"id"=>"D006505", "term"=>"Hepatitis"}, {"id"=>"D006521", "term"=>"Hepatitis, Chronic"}], "ancestors"=>[{"id"=>"D008107", "term"=>"Liver Diseases"}, {"id"=>"D004066", "term"=>"Digestive System Diseases"}, {"id"=>"D006525", "term"=>"Hepatitis, Viral, Human"}, {"id"=>"D014777", "term"=>"Virus Diseases"}, {"id"=>"D007239", "term"=>"Infections"}, {"id"=>"D004769", "term"=>"Enterovirus Infections"}, {"id"=>"D010850", "term"=>"Picornaviridae Infections"}, {"id"=>"D012327", "term"=>"RNA Virus Infections"}, {"id"=>"D000086982", "term"=>"Blood-Borne Infections"}, {"id"=>"D003141", "term"=>"Communicable Diseases"}, {"id"=>"D018347", "term"=>"Hepadnaviridae Infections"}, {"id"=>"D004266", "term"=>"DNA Virus Infections"}, {"id"=>"D002908", "term"=>"Chronic Disease"}, {"id"=>"D020969", "term"=>"Disease Attributes"}, {"id"=>"D010335", "term"=>"Pathologic Processes"}], "browseLeaves"=>[{"id"=>"M9592", "name"=>"Hepatitis A", "asFound"=>"Hepatitis", "relevance"=>"HIGH"}, {"id"=>"M9591", "name"=>"Hepatitis", "asFound"=>"Hepatitis", "relevance"=>"HIGH"}, {"id"=>"M9595", "name"=>"Hepatitis B", "asFound"=>"Hepatitis B", "relevance"=>"HIGH"}, {"id"=>"M21609", "name"=>"Hepatitis B, Chronic", "asFound"=>"Chronic Hepatitis B", "relevance"=>"HIGH"}, {"id"=>"M9607", "name"=>"Hepatitis, Chronic", "asFound"=>"Chronic Hepatitis", "relevance"=>"HIGH"}, {"id"=>"M11107", "name"=>"Liver Diseases", "relevance"=>"LOW"}, {"id"=>"M8883", "name"=>"Gastrointestinal Diseases", "relevance"=>"LOW"}, {"id"=>"M7255", "name"=>"Digestive System Diseases", "relevance"=>"LOW"}, {"id"=>"M9610", "name"=>"Hepatitis, Viral, Human", "relevance"=>"LOW"}, {"id"=>"M17522", "name"=>"Virus Diseases", "relevance"=>"LOW"}, {"id"=>"M10283", "name"=>"Infections", "relevance"=>"LOW"}, {"id"=>"M6368", "name"=>"Communicable Diseases", "relevance"=>"LOW"}, {"id"=>"M7930", "name"=>"Enterovirus Infections", "relevance"=>"LOW"}, {"id"=>"M13745", "name"=>"Picornaviridae Infections", "relevance"=>"LOW"}, {"id"=>"M15149", "name"=>"RNA Virus Infections", "relevance"=>"LOW"}, {"id"=>"M2593", "name"=>"Blood-Borne Infections", "relevance"=>"LOW"}, {"id"=>"M20487", "name"=>"Hepadnaviridae Infections", "relevance"=>"LOW"}, {"id"=>"M7442", "name"=>"DNA Virus Infections", "relevance"=>"LOW"}, {"id"=>"M6147", "name"=>"Chronic Disease", "relevance"=>"LOW"}, {"id"=>"M22700", "name"=>"Disease Attributes", "relevance"=>"LOW"}, {"id"=>"T1303", "name"=>"Chronic Graft Versus Host Disease", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Infections", "abbrev"=>"BC01"}, {"name"=>"Digestive System Diseases", "abbrev"=>"BC06"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Symptoms and General Pathology", "abbrev"=>"BC23"}, {"name"=>"Rare Diseases", "abbrev"=>"Rare"}]}, "interventionBrowseModule"=>{"browseLeaves"=>[{"id"=>"M16201", "name"=>"Sulfalene", "relevance"=>"LOW"}, {"id"=>"T367", "name"=>"Bifidobacterium", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Anti-Infective Agents", "abbrev"=>"Infe"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}, {"name"=>"Other Dietary Supplements", "abbrev"=>"Ot"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["NA"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"RANDOMIZED", "maskingInfo"=>{"masking"=>"SINGLE", "whoMasked"=>["PARTICIPANT"], "maskingDescription"=>"Double (Participant, Investigator)"}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"PARALLEL"}, "enrollmentInfo"=>{"type"=>"ESTIMATED", "count"=>100}}, "statusModule"=>{"overallStatus"=>"NOT_YET_RECRUITING", "startDateStruct"=>{"date"=>"2024-03", "type"=>"ESTIMATED"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2024-01", "completionDateStruct"=>{"date"=>"2025-04", "type"=>"ESTIMATED"}, "lastUpdateSubmitDate"=>"2024-01-23", "studyFirstSubmitDate"=>"2024-01-11", "studyFirstSubmitQcDate"=>"2024-01-23", "lastUpdatePostDateStruct"=>{"date"=>"2024-01-24", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"2024-01-24", "type"=>"ACTUAL"}, "primaryCompletionDateStruct"=>{"date"=>"2024-11", "type"=>"ESTIMATED"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Test the level of HBV infection in chronic hepatitis B patients", "timeFrame"=>"6 months", "description"=>"Evaluate HBsAg level in IU/mL"}]}, "oversightModule"=>{"isFdaRegulatedDrug"=>false, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"conditions"=>["Chronic Hepatitis B"]}, "descriptionModule"=>{"briefSummary"=>"The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV infection levels and regulating intestinal flora in patients with chronic hepatitis B.\n\nThe main question it aims to answer is:\n\n• Conventional antiviral therapy combined with a 6-month probiotic intervention was used to evaluate the clinical efficacy of reducing HBV infection levels (HBeAg, HBsAg, and HBV DNA levels) and regulating gut microbiota."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT", "OLDER_ADULT"], "maximumAge"=>"80 years", "minimumAge"=>"18 years", "healthyVolunteers"=>true, "eligibilityCriteria"=>"Inclusion Criteria:\n\n1. Meet the hepatitis B clinical diagnostic criteria of the Chronic Hepatitis B Prevention and Treatment Guidelines (2022 edition), excluding patients infected with hepatitis C virus, hepatitis D virus and other hepatitis viruses;\n2. Be aware of the content and purpose of this study, and voluntarily sign the treatment study consent.\n\nExclusion Criteria:\n\n1. Patients infected within 3 months;\n2. Received antibiotic treatment within 3 months;\n3. Received probiotic and probiotic therapy within 3 months;\n4. Complicated with hypertension or diabetes;\n5. Obesity or significantly low weight;\n6. Obvious atherosclerosis;\n7. Chronic kidney disease;\n8. Inflammatory bowel disease, irritable bowel syndrome, or a history of gastrointestinal surgery;\n9. Malignant tumors;\n10. Autoimmune diseases;\n11. Mental illnesses such as Parkinson's disease, Alzheimer's disease and stroke;\n12. Pregnant or lactating women;\n13. Patients with cirrhosis or decompensated liver disease;\n14. Subjects cannot participate in the experiment due to their reasons; Those who meet any of the above criteria will not be selected."}, "identificationModule"=>{"nctId"=>"NCT06221605", "briefTitle"=>"Regulation of Intestinal Flora by Compound Probiotics in Patients With Chronic Hepatitis B", "organization"=>{"class"=>"INDUSTRY", "fullName"=>"Wecare Probiotics Co., Ltd."}, "officialTitle"=>"Regulation of Intestinal Flora by Compound Probiotics in Patients With Chronic Hepatitis B: a Randomized, Double-blind, Placebo-controlled Study", "orgStudyIdInfo"=>{"id"=>"WK2023009"}}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"Probiotic group", "description"=>"15B CFU/sachet/day, before meals; Compound Probiotics (Bifidobacterium animalis subsp. animalis BLa80、Bifidobacterium longum subsp. longum BL21、Lacticaseibacillus rhamnosus LRa05) Storage: store in a cool, dry place without sun exposure.", "interventionNames"=>["Dietary Supplement: Probiotic"]}, {"type"=>"PLACEBO_COMPARATOR", "label"=>"placebo", "description"=>"Maltodextrin, 1 sachet/day, before meals; Storage: store in a cool, dry place without sun exposure.", "interventionNames"=>["Dietary Supplement: Probiotic"]}], "interventions"=>[{"name"=>"Probiotic", "type"=>"DIETARY_SUPPLEMENT", "description"=>"The intervention lasted for 6 months and 3 visits (at 0 month, 3rd and 6th month respectively).", "armGroupLabels"=>["Probiotic group", "placebo"]}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Wecare Probiotics Co., Ltd.", "class"=>"INDUSTRY"}, "responsibleParty"=>{"type"=>"SPONSOR"}}}}
